For a study, researchers sought to discuss the function of glucagon-like peptide-1 (GLP-1) receptor signaling in lowering lung inflammation and the possible use of GLP-1 receptor agonists (GLP-1RAs) in asthma therapy. Although GLP-1RA was used to treat type 2 diabetes (T2D) and obese weight loss, there was a lot of interest in broadening the indications for usage in other conditions, such as inflammatory pulmonary disease. GLP-1RA decreases airway inflammation, obstruction, and fibrosis in animal models of acute and chronic pulmonary illness. GLP-1 receptor (GLP-1R) signaling, in particular, appeared to decrease allergen-induced type 2 inflammation, making it an appealing treatment for asthma. The findings were especially encouraging in disease processes characterized by disrupted metabolic control, such as T2D or metabolic syndrome. Although prospective human trials were sparse, retrospective clinical research showed encouraging evidence for the use of GLP-1RAs in concomitant diabetes and asthma.

In the section, researchers described the biology of GLP-1 and GLP-1R signaling, examined preclinical and mechanistic evidence for how GLP-1R signaling may reduce pulmonary inflammation, and outlined current and forthcoming clinical investigations. Finally, inhibiting GLP-1R signaling may constitute a unique strategy for glucocorticoid sparing and perhaps disease-modifying asthma treatment.

Reference:journals.lww.com/co-allergy/Abstract/2022/02000/Evaluating_the_glucagon_like_peptide_1_receptor_in.7.aspx